{"id":390653,"date":"2018-06-11T00:00:00","date_gmt":"2018-06-11T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/biosbi0006-2018-biopharma-biosimilars-access-reimbursement-global-2018\/"},"modified":"2026-03-31T10:48:22","modified_gmt":"2026-03-31T10:48:22","slug":"biosbi0006-2018-biopharma-biosimilars-access-reimbursement-global-2018","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/biosbi0006-2018-biopharma-biosimilars-access-reimbursement-global-2018\/","title":{"rendered":"Biosimilars | Access &#038; Reimbursement | Global | 2018"},"content":{"rendered":"<p>The regulatory and market access landscape for biosimilars is constantly evolving. For a company seeking to develop a biosimilar for multiple markets, keeping track of the similarities and differences in different countries can be a significant challenge. The Access &#038; Reimbursement Overview allows rapid assessment of key market access parameters across the United States, EU5, Japan, Australia, Canada, and key emerging\u00a0markets.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul>\n<li>Does a dedicated biosimilar pathway exist in the country of interest?<\/li>\n<li>What types of biological products fall within the scope of biosimilar guidance?<\/li>\n<li>What are the regulatory considerations with regard to reference-product selection?<\/li>\n<li>Is automatic pharmacy-level substitution permitted?<\/li>\n<li>What pricing mechanisms exist for biosimilars and their reference products?<\/li>\n<li>Is the local government actively driving biosimilar uptake?<\/li>\n<\/ul>\n<p><strong>Key markets covered<\/strong><\/p>\n<p>France, Germany, Italy, Spain, United Kingdom, United States, Japan, Australia, Brazil, Canada, China, India, Mexico, Russia, and\u00a0South Korea.<\/p>\n<p><strong>Key companies mentioned<\/strong><\/p>\n<ul>\n<li>Amgen<\/li>\n<li>Boehringer Ingelheim<\/li>\n<li>Celltrion<\/li>\n<li>Eli Lilly<\/li>\n<li>Hospira<\/li>\n<li>Merck &#038; Co.<\/li>\n<li>Mylan<\/li>\n<li>Pfizer<\/li>\n<li>Roche<\/li>\n<li>Samsung Bioepis<\/li>\n<li>Sandoz<\/li>\n<\/ul>\n<p><strong>Key drugs mentioned<\/strong><\/p>\n<ul>\n<li>Avastin<\/li>\n<li>Basaglar<\/li>\n<li>Benepali<\/li>\n<li>Binocrit<\/li>\n<li>Brenzys<\/li>\n<li>Enbrel<\/li>\n<li>Herceptin<\/li>\n<li>Humira<\/li>\n<li>Inflectra<\/li>\n<li>Neulasta<\/li>\n<li>Nivestim<\/li>\n<li>Remicade<\/li>\n<li>Renflexis<\/li>\n<li>Remsima<\/li>\n<li>Rituxan\/MabThera<\/li>\n<li>Truxima<\/li>\n<li>Zarzio\/Zarxio<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-390653","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-product-biosimilars","biopharma-date-920"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390653","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390653\/revisions"}],"predecessor-version":[{"id":576731,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390653\/revisions\/576731"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390653"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}